

Section 1: IDENTIFICATION

Product Name: PerioPlus #3
Synonyms: Not available.
Product Use: Mouthwash.
Restrictions on Use: Not available.
Manufacturer/Supplier: Canadian Hospital Specialities Ltd.
2810 Coventry RD
Oakville, ON L6H 6R1
Phone Number: (905) 825-9300
Emergency Phone: (905) 825-9300
Date of Preparation of SDS: July 20, 2022

Section 2: HAZARD(S) IDENTIFICATION

GHS INFORMATION

Classification: Not hazardous according to OSHA criteria (29 CFR 1910.1200).
Not hazardous according to WHMIS 2015 criteria.

LABEL ELEMENTS

Hazard None.

Pictogram(s):

Signal Word: None.

Hazard Statements: Not applicable.

Precautionary Statements

Prevention: Not applicable.

Response: Not applicable.

Storage: Not applicable.

Disposal: Not applicable.

Prevention: Not applicable.

Hazards Not Otherwise Classified: Not applicable.

Ingredients with Unknown Toxicity: None.

This material is not considered hazardous by the OSHA Hazard Communication Standard, (29 CFR 1910.1200).

This material is not considered hazardous by the Hazardous Products Regulations.

Section 3: COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient(s)	Common name / Synonyms	CAS No.	% wt./wt.
Water	Not available.	7732-18-5	90 - 95
Xylitol	Not available.	87-99-0	3 - 7
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.	Polysorbate 20	9005-64-5	0.1 - 0.5
Pyridinium, 1-hexadecyl-, chloride (1:1)	Cetylpyridinium chloride	123-03-5	< 0.1
Benzoic acid, 2-hydroxy-, methyl ester	Methyl salicylate	119-36-8	< 0.1
1,2,3-Propanetriol	Glycerin	56-81-5	< 0.1
D-Gluconic acid, compd. with N1,N14-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediiimide (2:1)	Chlorhexidine gluconate	18472-51-0	< 0.1
Benzenemethanol	Benzyl alcohol	100-51-6	< 0.1
Sodium carbonate	Not available.	5968-11-6	< 0.1
Benzenemethanaminium, N-ethyl-N-[4-[[4-[ethyl[(3-sulfophenyl)methyl]amino]phenyl](2-sulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-3-sulfo-, inner salt, sodium salt (1:2)	Brilliant Blue	3844-45-9	< 0.1
1H-Pyrazole-3-carboxylic acid, 4,5-dihydro-5-oxo-1-(4-sulfophenyl)-4-[2-(4-sulfophenyl)diazenyl]-, sodium salt (1:3)	Tartrazine	1934-21-0	< 0.1

Section 4: FIRST-AID MEASURES

Inhalation: No first-aid measures are necessary when product is used as recommended. If significant amounts of vapours are inhaled: Call a doctor if you feel unwell.

Acute and delayed symptoms and effects: Not expected to cause any harmful effects under normal conditions of use. Inhalation of large amounts of vapours may cause respiratory irritation. Signs/symptoms may include cough, sneezing, nasal discharge, headache, hoarseness, and nose and throat pain.

Eye Contact: If in eyes: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Call a doctor if you feel unwell.

Acute and delayed symptoms and effects: Not expected to cause any harmful effects under normal conditions of use. Droplets may cause eye irritation. Signs/symptoms may include redness, swelling, pain, tearing, and blurred or hazy vision.

Skin Contact: No first-aid measures are necessary when product is used as recommended. If large amounts of product come in contact with skin: Wash with plenty of water. Call a doctor if you feel unwell.

Acute and delayed symptoms and effects: Not expected to cause any harmful effects under normal conditions of use. Contact with large amounts of product may cause skin irritation. Signs/symptoms may include localized redness, swelling, and itching.

Ingestion: Inadvertent swallowing of small amounts of product during normal use is not expected to cause any harmful effects. Do not exceed the recommended dosage. If large amounts are swallowed: Call a doctor if you feel unwell. If vomiting occurs naturally, have victim lean forward to reduce the risk of aspiration. Do NOT induce vomiting unless directed to do so by medical personnel.

Acute and delayed symptoms and effects: Not expected to cause any harmful effects under normal conditions of use. Intentional ingestion of large amounts of this product may cause gastrointestinal irritation. Signs/symptoms may include abdominal pain, stomach upset, nausea, vomiting and diarrhea.

General Advice: In case of accident or if you feel unwell, seek medical advice immediately (show the label or SDS where possible).

Note to Physicians: Symptoms may not appear immediately.

Section 5: FIRE-FIGHTING MEASURES

FLAMMABILITY AND EXPLOSION INFORMATION

Not flammable or combustible by OSHA/WHMIS criteria.

Sensitivity to Mechanical Impact: This material is not sensitive to mechanical impact.

Sensitivity to Static Discharge: This material is not sensitive to static discharge.

MEANS OF EXTINCTION

Suitable Extinguishing Media: Small Fire: Dry chemical, CO₂, water spray or regular foam.

Large Fire: Water spray, fog or regular foam. Move containers from fire area if you can do it without risk.

Unsuitable Extinguishing Media: Not available.

Products of Combustion: Oxides of carbon.

Protection of Firefighters: Fire may produce irritating, corrosive and/or toxic gases. Runoff from fire control or dilution water may cause pollution. Wear positive pressure self-contained breathing apparatus (SCBA). Structural firefighters' protective clothing will only provide limited protection.

Section 6: ACCIDENTAL RELEASE MEASURES

Emergency Procedures: Not necessary for small spills. For large spills: Keep unauthorized personnel away. Stay upwind. Keep out of low areas. Ventilate closed spaces before entering.

Personal Precautions: Not necessary for small spills. Keep container closed. For large spills: Use personal protection recommended in Section 8.



Environmental Precautions: Not necessary for small spills. For large amounts: Keep out of drains, sewers, ditches, and waterways.

Methods for Containment: Large Spills: Stop leak if without risk.

Methods for Clean-Up: Small spills: Wipe up with absorbent material. Large spills: Absorb or cover with dry earth, sand or other non-combustible material and transfer to containers.

Other Information: See Section 13 for disposal considerations.

Section 7: HANDLING AND STORAGE

Handling:

Avoid getting in eyes. See Section 8 for information on Personal Protective Equipment.

Storage:

Store away from incompatible materials. See Section 10 for information on Incompatible Materials. Keep out of the reach of children.

Section 8: EXPOSURE CONTROLS / PERSONAL PROTECTION

Exposure Guidelines

Component

Water [CAS No. 7732-18-5]

ACGIH: No TLV established.

OSHA: No PEL established.

Xylitol [CAS No. 87-99-0]

ACGIH: No TLV established.

OSHA: No PEL established.

Polysorbate 20 [CAS No. 9005-64-5]

ACGIH: No TLV established.

OSHA: No PEL established.

Cetylpyridinium chloride [CAS No. 123-03-5]

ACGIH: No TLV established.

OSHA: No PEL established.

Methyl salicylate [CAS No. 119-36-8]

ACGIH: No TLV established.

OSHA: No PEL established.

Glycerin [CAS No. 56-81-5]

ACGIH: No TLV established.

OSHA: 15 mg/m³ (Total particulate) (TWA), 5 mg/m³ (Respirable fraction) (TWA);
10 mg/m³ (Total particulate) (TWA) [Vacated];

Chlorhexidine gluconate [CAS No. 18472-51-0]

ACGIH: No TLV established.

OSHA: No PEL established.

Benzyl alcohol [CAS No. 100-51-6]

ACGIH: No TLV established.

OSHA: No PEL established.

Sodium carbonate [CAS No. 5968-11-6]

ACGIH: No TLV established.

OSHA: No PEL established.

Brilliant Blue [CAS No. 3844-45-9]

ACGIH: No TLV established.

OSHA: No PEL established.

Tartrazine [CAS No. 1934-21-0]

ACGIH: No TLV established.

OSHA: No PEL established.

PEL: Permissible Exposure Limit

TLV: Threshold Limit Value

TWA: Time-Weighted Average

Engineering Controls:

Use ventilation adequate to keep exposures (airborne levels of dust, fume, vapour, gas, etc.) below recommended exposure limits.

PERSONAL PROTECTIVE EQUIPMENT (PPE)



Eye/Face Protection:

Not required under normal conditions of use. Wear safety glasses when handling large amounts. Use equipment for eye protection that meets the standards referenced by CSA Standard CAN/CSA-Z94.3:20 and OSHA regulations in 29 CFR 1910.133 for Personal Protective Equipment.

Hand Protection:

Not required under normal conditions of use. Wear protective gloves when handling large amounts. Consult manufacturer specifications for further information.

Skin and Body Protection:

Not required under normal conditions of use. Wear protective clothing when handling large amounts.

Respiratory Protection:

Not required under normal use conditions.

General Hygiene Considerations:

Handle according to established industrial hygiene and safety practices. Consult a competent industrial hygienist to determine hazard potential and/or the PPE manufacturers to ensure adequate protection.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

Appearance:

Clear liquid.

Colour:

Light green.



SAFETY DATA SHEET

PerioPlus #3

Date of Preparation: July 20, 2022

Odour:	Aromatic.
Odour Threshold:	Not available.
Physical State:	Liquid.
pH:	Not available.
Melting Point / Freezing Point:	Not available.
Initial Boiling Point:	Not available.
Boiling Range:	Not available.
Flash Point:	Not available.
Evaporation Rate:	Not available.
Flammability (solid, gas):	Not applicable.
Lower Flammability Limit:	Not available.
Upper Flammability Limit:	Not available.
Vapor Pressure:	Not available.
Vapor Density:	Not available.
Relative Density:	Not available.
Solubilities:	Not available.
Partition Coefficient: n-Octanol/Water:	Not available.
Auto-ignition Temperature:	Not available.
Decomposition Temperature:	Not available.
Viscosity:	Not available.
Percent Volatile, wt. %:	Not available.
VOC content, wt. %:	Not available.
Density:	Not available.
Coefficient of Water/Oil Distribution:	Not available.

Section 10: STABILITY AND REACTIVITY

Reactivity:	Contact with incompatible materials. Exposure to heat.
Chemical Stability:	Stable under normal storage conditions.
Possibility of Hazardous Reactions:	None known.
Conditions to Avoid:	Contact with incompatible materials. Exposure to heat.
Incompatible Materials:	Strong oxidizers.
Hazardous Decomposition Products:	Not available.

Section 11: TOXICOLOGICAL INFORMATION

EFFECTS OF ACUTE EXPOSURE

Product Toxicity

Oral: Not available.

Dermal: Not available.

Inhalation: Not available.

Component Toxicity

Component	CAS No.	LD ₅₀ oral	LD ₅₀ dermal	LC ₅₀
Water	7732-18-5	> 90 mL/kg (rat)	Not available.	Not available.
Xylitol	87-99-0	16500 mg/kg (rat)	Not available.	Not available.
Polysorbate 20	9005-64-5	18 mL/kg (hamster)	Not available.	Not available.
Cetylpyridinium chloride	123-03-5	200 mg/kg (rat)	2000 mg/kg (rabbit)	90 mg/m ³ (rat); 4H
Methyl salicylate	119-36-8	887 mg/kg (rat)	Not available.	Not available.
Glycerin	56-81-5	12600 mg/kg (rat)	> 10000 mg/kg (rabbit)	> 570 mg/m ³ (rat); 1H
Chlorhexidine gluconate	18472-51-0	2000 mg/kg (rat)	Not available.	Not available.
Benzyl alcohol	100-51-6	1040 mg/kg (rabbit)	2000 mg/kg (rabbit)	Not available.
Sodium carbonate	5968-11-6	Not available.	Not available.	Not available.
Brilliant Blue	3844-45-9	Not available.	Not available.	Not available.
Tartrazine	1934-21-0	12750 mg/kg (mouse)	Not available.	Not available.

Likely Routes of Exposure: Eye contact. Skin contact. Inhalation. Ingestion. Skin absorption.

Target Organs: Skin. Eyes. Gastrointestinal tract.

Symptoms (including delayed and immediate effects)

Inhalation: Not expected to cause any harmful effects under normal conditions of use. Inhalation of large amounts of vapours may cause respiratory irritation. Signs/symptoms may include cough, sneezing, nasal discharge, headache, hoarseness, and nose and throat pain.

Eye: Not expected to cause any harmful effects under normal conditions of use. Droplets may cause eye irritation. Signs/symptoms may include redness, swelling, pain, tearing, and blurred or hazy vision.

Skin: Not expected to cause any harmful effects under normal conditions of use. Contact with large amounts of product may cause skin irritation. Signs/symptoms may include localized redness, swelling, and itching.

Ingestion: Not expected to cause any harmful effects under normal conditions of use. Intentional ingestion of large amounts of this product may cause gastrointestinal irritation. Signs/symptoms may include abdominal pain, stomach upset, nausea, vomiting and diarrhea.

Skin Sensitization: Not available.



SAFETY DATA SHEET

PerioPlus #3

Date of Preparation: July 20, 2022

Respiratory Sensitization: Not available.

Medical Conditions Not available.

Aggravated By Exposure:

EFFECTS OF CHRONIC EXPOSURE (from short and long-term exposure)

Target Organs: Skin. Eyes. Gastrointestinal tract.

Chronic Effects: Prolonged or repeated contact may dry skin and cause irritation.

Carcinogenicity: This product does not contain any carcinogens or potential carcinogens above reportable thresholds as listed by ACGIH, IARC, OSHA, or NTP.

Component Carcinogenicity

Component	ACGIH	IARC	NTP	OSHA	Prop 65
Brilliant Blue	Not listed.	Group 3	Not listed.	Not listed.	Not listed.

Mutagenicity: Contains no ingredient listed as mutagenic or genotoxic.

Reproductive Effects: Contains no ingredient listed as toxic to reproduction.

Developmental Effects

Teratogenicity: Not available.

Embryotoxicity: Not available.

Toxicologically Synergistic Materials: Not available.

Section 12: ECOLOGICAL INFORMATION

Ecotoxicity: Not available.

Persistence / Degradability: Not available.

Bioaccumulation / Accumulation: Not available.

Mobility in Environment: Not available.

Other Adverse Effects: Not available.

Section 13: DISPOSAL CONSIDERATIONS

Disposal Instructions: Disposal should be in accordance with applicable regional, national and local laws and regulations. Local regulations may be more stringent than regional or national requirements.

Section 14: TRANSPORT INFORMATION

U.S. Department of Transportation (DOT)

Proper Shipping Name: Not regulated.

Class: Not applicable.

UN Number: Not applicable.

Packing Group: Not applicable.

Placard(s): Not applicable.



SAFETY DATA SHEET

PerioPlus #3

Date of Preparation: July 20, 2022

Canada Transportation of Dangerous Goods (TDG)

Proper Shipping Name: Not regulated.

Class: Not applicable.

UN Number: Not applicable.

Packing Group: Not applicable.

Placard(s): Not applicable.

Section 15: REGULATORY INFORMATION

Federal Regulations

United States

This SDS has been prepared to meet the U.S. OSHA Hazard Communication Standard, 29 CFR 1910.1200.

SARA Title III

No components are listed.

State Regulations

Massachusetts

US Massachusetts Commonwealth's Right-to-Know Law (Appendix A to 105 Code of Massachusetts Regulations Section 670.000)

No components are listed.

New Jersey

US New Jersey Worker and Community Right-to-Know Act (New Jersey Statute Annotated Section 34:5A-5)

No components are listed.

Pennsylvania

US Pennsylvania Worker and Community Right-to-Know Law (34 Pa. Code Chap. 301-323)

No components are listed.

Section 16: OTHER INFORMATION

Disclaimer:

The information contained in this document applies to this specific material as supplied. It may not be valid for this material if it is used in combination with any other materials. It is the user's responsibility to satisfy oneself as to the suitability and completeness of this information for their own particular use.

Date of Preparation of SDS: July 20, 2022

Version: 1.0

GHS SDS Prepared by: Aegis Regulatory Inc.

Phone: 1 (519) 488-0351

www.aegisreg.com